Stocks · News reference
Niagen Bioscience Widens FY2026 Sales Guidance of $138.982M-$145.299M vs $141.072M Est
Niagen Bioscience (NASDAQ:NAGE) widens FY2026 sales outlook from $138.982 million-$145.299 million to $138.982 million-$145.299 million vs $141.072 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Transcript: Niagen Bioscience Q2 2026 Earnings Conference Call
Niagen Bioscience (NASDAQ:NAGE) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
Niagen Bioscience Highlights Preclinical Research Linking CD38-Driven NAD+ Depletion To Placental Aging; NOTE: Niagen Bioscience Did Not Conduct, Fund, Or Design This Study, And The NR Used Was Not The Company’s Niagen Ingredient
Preclinical study results showcase that CD38, an NAD-consuming enzyme more active with age and inflammation, leads to NAD+ depletion in placental tissue, while restoring NAD+ with the precursor NR improved placental,
Niagen Bioscience Announces Online And Retail Availability Of Tru Niagen At GNC And Sam's Club Locations Across 44 States